Lantheus (LNTH) Q1 2026 Earnings
How Did LNTH Stock React to Q1 2026 Earnings?
S&P 500 over the same 30 days: +0.75%.
Did LNTH Beat Earnings? Q1 2026 Results
Yes. Lantheus reported Q1 2026 earnings of $1.46 a share on May 7, 2026, beating the $1.23 consensus estimate by 18.8%. Revenue was $377.3M against a $354.4M estimate.
Lantheus delivered a clear beat to open fiscal 2026, posting first-quarter revenue of $377.33 million, up 1.2% year over year and ahead of the $354.42 million consensus by 6.46%, while adjusted EPS of $1.46 topped the $1.23 estimate by 18.78%. The headline driver was a portfolio in transition: PYLARIFY, the company's flagship PSMA PET imaging agent, faced competitive pressure that trimmed its contribution to $240.92 million, but that softness was offset by Neuraceq's $35.44 million addition following the Life Molecular Imaging acquisition and DEFINITY's 6.8% growth to $84.63 million. A significant regulatory catalyst added further momentum, as the FDA approved PYLARIFY TruVu, a reformulated version designed for manufacturing efficiency, with a phased commercial launch targeted for Q4 2026. Analysts raised price targets following the results, with shares responding positively to the combination of the beat and pipeline progress. Management reaffirmed full-year 2026 guidance of $1.40 billion to $1.45 billion in revenue and adjusted EPS of $5.00 to $5.25, pointing to accelerating growth beginning in 2027.
- Strong DEFINITY sales growth of 6.8% year over year
- Addition of Neuraceq revenue ($35.4 million) as a new revenue line in neurology
- Gain on sale of SPECT business boosted GAAP net income
- Strategic partnerships and other revenue grew 52.1%
“Our first quarter results demonstrate disciplined execution across the business, with strong performance from PYLARIFY, Neuraceq, and DEFINITY, and continued progress against the priorities that underpin our long-term strategy.”
Lantheus CEO, on the earnings call
What Was Lantheus's Outlook in Q1 2026?
Lantheus reaffirmed its full-year 2026 guidance: revenue of $1.4 billion to $1.45 billion and adjusted fully diluted EPS of $5.00 to $5.25, unchanged from guidance issued on February 26, 2026. The company plans a phased geographic launch of PYLARIFY TruVu beginning in Q4 2026, is focused on sustaining PSMA PET leadership, expanding its Alzheimer's imaging portfolio, and advancing its prioritized pipeline. Management indicated growth acceleration is expected beginning in 2027 and signaled disciplined capital deployment focused on radiodiagnostics while evaluating value-maximizing alternatives for radiotherapeutic assets.
LNTH YoY Financials
| Metric | Q1 2026 | Q1 2025 | Year over year |
|---|---|---|---|
| Revenue | $377.3M | $372.7M | +1.2% |
| Gross Profit | $230.9M | $237.7M | −2.9% |
| Operating Income | $81.3M | $102.1M | −20.3% |
| Net Income | $118.4M | $72.9M | +62.3% |
LNTH Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.